The Cancer Mechanisms (CM) Program of The Tisch Cancer Institute (TCI) is comprised of 49 members who share a common goal to catalyze basic research pertinent to cancer-relevant mechanistic discovery with the ultimate goal of generating new knowledge that will lead to improving the diagnosis, treatment, and prevention of primary cancer and systemic cancer recurrence in our unique catchment area across three key themes: 1. CELL AND NICHE BIOLOGY, 2. CELL SIGNALING NETWORKS and 3. CHROMATIN AND GENE REGULATION (see Figure 1 in the Research Strategy). Principal investigators in CM represent 15 Departments and 10 Institutes. As of February 2019, CM program members were awarded over $17 million in direct cost funding, with NCI support of $4.7 million and peer- reviewed cancer-related support of $13.7 million. In 2018, the program published 82 papers of which 22% were intra- and 17% were inter-programmatic. Our premise is that basic research focused on genetic, epigenetic, biochemical, micro-environmental, and developmental pathways that drive primary cancer initiation and maintenance, minimal residual disease, dormancy and overt metastasis, will reveal novel biomarkers and therapeutic targets to address each of these stages across both liquid and solid tumors.
We aim to elucidate critical mechanisms across the three CM themes and foster intra- and inter-program collaborations in order to accelerate the transfer of discoveries into translational and clinical efforts. We will achieve this goal using orchestrated intra-programmatic efforts within CM themes (e.g. working groups, monthly meetings), and inter-programmatic collaborations with other programs such as Cancer Clinical Investigation (CCI), Cancer Prevention and Control (CPC) and Cancer Immunology (CI) or with disease focus groups such as Liver Cancer. In particular, our new strategic plan allows CM investigators, upon identifying targets, biomarkers or molecules for therapeutic intervention, to work closely with the newly created CCI program, which facilitates an accelerated translational or clinical path. Finally, our strategic plan will facilitate new collaborative research, training and education opportunities within our program and in our community (via efforts with CPC), high-impact publications, MPI/P01 submissions, clinical trials and translational output through partnership with CCI, and other team efforts that encompass CM's exceptional science.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022665
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Deshmukh, Manjeet; Nakagawa, Shigeki; Higashi, Takaaki et al. (2018) Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine 14:317-325
Van Renne, Nicolaas; Roca Suarez, Armando Andres; Duong, Francois H T et al. (2018) miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut 67:953-962
Trépo, Eric; Goossens, Nicolas; Fujiwara, Naoto et al. (2018) Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology 154:965-975
Hu, Liangyuan; Hogan, Joseph W; Mwangi, Ann W et al. (2018) Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection. Biometrics 74:703-713
Ferrara, James L M; Chaudhry, Mohammed S (2018) GVHD: biology matters. Hematology Am Soc Hematol Educ Program 2018:221-227
Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia et al. (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37:3740-3752
Mascarenhas, J; Virtgaym, E; Stal, M et al. (2018) Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol 97:1369-1374
Wu, Lisa M; Amidi, Ali; Valdimarsdottir, Heiddis et al. (2018) The Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors. J Clin Sleep Med 14:31-39
Miller, Albert; Szeinuk, Jaime; Noonan, Curtis W et al. (2018) Libby Amphibole Disease: Pulmonary Function and CT Abnormalities in Vermiculite Miners. J Occup Environ Med 60:167-173
Vuong, Linh T; Iomini, Carlo; Balmer, Sophie et al. (2018) Kinesin-2 and IFT-A act as a complex promoting nuclear localization of ?-catenin during Wnt signalling. Nat Commun 9:5304

Showing the most recent 10 out of 143 publications